Gilead's Kite Subsidiary to Buy Penn Spinout Interius BioTherapeutics

Gilead Sciences Gains In Vivo Cell Therapy Capability With $350M Interius Bio Acquisition

Gilead Sciences, whose Kite subsidiary was one of the pioneers of ex vivo cancer cell therapy, is joining the pursuit of in vivo therapies with the acquisition of startup Interius BioTherapeutics. The deal follows AstraZeneca and AbbVie acquisitions this year for in vivo cell therapy developers.

Gilead buys in vivo cell therapy firm Interius for $350m

Gilead's Kite unit has reached an agreement to buy Interius BioTherapeutics, boosting its in vivo cell therapy credentials.

Gildea's Kite Pharma Just Acquired Interius—$350 Million Move Shakes Up Cancer Therapy - Gilead Sciences (NASDAQ:GILD)

As biotechnology companies increasingly seek innovative approaches to enhance cancer treatment, strategic acquisitions are becoming a key pathway for expanding capabilities and integrating advanced therapeutic platforms. Kite Pharma, a Gilead Sciences Inc. company (NASDAQ:GILD) on Thursday agreed to acquire Interius BioTherapeutics, a privately held biotechnology company developing in vivo CAR therapeutics, for $350 million. The acquisition comp…

Gilead’s Kite Pharma acquires Interius BioTherapeutics for $350 million

Gilead subsidiary Kite Pharma said Thursday that it has acquired Interius BioTherapeutics and its single-shot CAR-T program for $350 million. It’s the latest move in a high-stakes race to develop a simpler, safer, and more scalable version of the cell therapies that have proven powerful in treating certain blood cancers.  Typically, CAR-Ts are produced ex vivo, meaning patients’ immune cells are removed, engineered in a facility to target their …

Gilead's Kite subsidiary to buy Penn spinout Interius BioTherapeutics

Gilead dives into ‘in vivo’ cell therapy with $350M buyout of Interius

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.